Sughrue Mion, PLLC
Anti-CXADR antibody
An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.
MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. MICROBIAL CHEMISTRY RESEARCH FOUNDATION
A C G G A C C G A C C C C
A61K C07K G01N G01N A61P C07K C07K G01N A61K C07K C07K C07K C07K
additional inventional additional inventional inventional inventional additional inventional additional additional additional additional inventional
Sakiko Masunori Masahito Manabu Hiroyuki Shuichi
Urano Kajikawa Sugiura Kawada Inoue Sakamoto